Nexara Health — Health Canada Drug Establishment Licence #3-002896

ZADITOR 0.25 MG

Last verified 2026-09-10 · Source: Health Canada Drug Product Database (DPD), DIN 02242324

ZADITOR 0.25 MG — DIN 02242324

KETOTIFEN (KETOTIFEN FUMARATE) : 0.25 MG · LABORATOIRES THEA · SOLUTION · wholesale supply in Canada

Health Canada status: MARKETED

What is ZADITOR?

ZADITOR 0.25 MG contains KETOTIFEN (KETOTIFEN FUMARATE) : 0.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02242324, held by LABORATOIRES THEA, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 10-Aug-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is ZADITOR used for?

Treatment of allergic conjunctivitis.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How much does Ketotifen cost around the world?

Ketotifen is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listedRange
Saudi Arabiapublic1919SAR███.██
Greeceproducer price (ex-factory)88EUR███.██
South Africasingle exit price35ZAR███.██
Romaniamax producer price44RON███.██
Bahrainretail (max)33BHD███.██
United Statesacquisition13USD███.██
Czechiamax producer price (ex-factory)12CZK███.██
Icelandmax wholesale12ISK███.██
United Arab Emiratespublic11AED███.██

47 pack listings across 41 brand entries and 8 price bases, refreshed 03 Sep 2026. Ranges span every Ketotifen pack in that market, so a high figure is usually a larger pack rather than the same product.

Figures are held for the Nexara team. Cross-market prices are published on incompatible bases and are not an offer, a landed cost, or a guide to what any buyer can obtain. Nexara publishes which markets list the product and on what basis; the numbers stay internal.

Team sign-in

Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.

Ask Nexara for a landed Canadian price

Is there a generic Ketotifen in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

4 holders have a Canadian DIN containing Ketotifen, across 5 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
JAMP PHARMA CORPORATION21JAMP KETOTIFEN, JAMP KETOTIFEN OPHTHALMICSourceable in Canada
LABORATOIRES THEA11ZADITORSourceable in Canada
NOVARTIS PHARMACEUTICALS CANADA INC10ZADITORNo marketed DIN
STERIMAX INC10KETOTIFEN OPHTHALMIC SOLUTIONNo marketed DIN

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label0.25 MG
Dosage formSOLUTION
RouteOPHTHALMIC
Pack configuration (monograph)Multi-dose white plastic bottles with controlled dropper tips containing 5 mL of clear solution.
StorageStore between 4°C and 25°C. After opening the bottle, the eye drops can only be stored for 4 weeks.

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Substance and classification

Active substanceKetotifen
ATC codeS01GX08
AHFS class56:28.12
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02242324
DIN (unpadded, as printed on some documents)2242324
Brand nameZADITOR
Generic / active ingredientKETOTIFEN (KETOTIFEN FUMARATE) : 0.25 MG
Market authorization holderLABORATOIRES THEA
Health Canada schedulePrescription
ATC codeS01GX08
ATC anatomical main groupS — Sensory organs
ATC therapeutic subgroupS01GX
Current statusMARKETED
Status date10-Aug-2012
Original market date2000-07-11 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

How is it administered?

One drop in the affected eye(s) every 8 to 12 hours. Use nasolacrimal occlusion for 1-2 minutes after administration to reduce systemic absorption.

Included because it drives pack selection and wastage. Consult the monograph.

Contraindications

Hypersensitivity to this drug or to any ingredient in the formulation or component of the container.

Warnings and precautions

For topical use only. Contains benzalkonium chloride; remove soft contact lenses before use and wait 15 mins. May cause blurred vision or somnolence; avoid driving if affected.

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

2 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
JAMP KETOTIFEN OPHTHALMIC0.25 MGSOLUTIONJAMP PHARMA CORPORATIONMARKETED02542722
JAMP KETOTIFEN0.025 % W/VSOLUTIONJAMP PHARMA CORPORATIONAPPROVED02489651
KETOTIFEN OPHTHALMIC SOLUTION0.25 MGSOLUTIONSTERIMAX INCDORMANT02400871
ZADITOR0.25 MGSOLUTIONNOVARTIS PHARMACEUTICALS CANADA INCCANCELLED POST MARKET02279223

2 · Same class — other molecules in ATC S01GX

MoleculeCanadian brandsDINsMarketedSourceable
OlopatadineACT OLOPATADINE 0.1% · ACT OLOPATADINE 0.2% · APO-OLOPATADINE · JAMP-OLOPATADINE · +12 more179Yes
KetotifenJAMP KETOTIFEN · JAMP KETOTIFEN OPHTHALMIC · KETOTIFEN OPHTHALMIC SOLUTION · ZADITOR52Yes
Cromoglicic AcidALLERGAN EYE ITCH RELIEF · ANTI-ALLERGY EYE DROPS · CROMOLYN EYE DROPS · OPTICROM · +4 more81Yes
LodoxamideALOMIDE11Yes
NedocromilALOCRIL · MIREZE20Not in Canada
LevocabastineLIVOSTIN EYE DROPS10Not in Canada
EmedastineEMADINE10Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC S01G

ATC subgroupMoleculesDINsMarketed
S01GANaphazoline · Naphazoline, Combinations · Oxymetazoline · Phenylephrine · Phenylephrine, Combinations · +3 more7517

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

What else is ZADITOR called?

The same molecule, Ketotifen, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
ZaditenLatinSouth Africa
KetotifenLatinIceland
KETOTIFEN ALLatinCzechia
Adco-KetotifenLatinSouth Africa
Adco-ZetofenLatinSouth Africa
APIZADLatinBahrain
ASMAFORTLatinBahrain
FenobatLatinSaudi Arabia
HISTOFENLatinSaudi Arabia
KetaLatinSaudi Arabia
PROFILARLatinBahrain

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for ZADITOR

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Related pages

Sourcing this product